Bortezomib (PS-341)

目录号:S1013 别名: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。

规格 价格 库存 购买数量  
RMB 571.94 现货
RMB 2188.92 现货
RMB 5488.32 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献156篇:

客户使用该产品的25个实验数据:

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

产品安全说明书

Proteasome抑制剂选择性比较

生物活性

产品描述 Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。
靶点
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外研究

Bortezomib,一种硼酸二肽,是一种26S蛋白酶体的高选择性可逆抑制剂,其作用于错误折叠蛋白的降解,并且对细胞周期的调控是必要的。暴露于Bortezomib能够稳定p21,p27,和p53,以及促凋亡Bid和Bax蛋白,微囊蛋白-1,和抑制剂κB-α,这防止了核因子κB诱导的细胞存活途径的激活。Bortezomib也会促进促凋亡c-Jun-NH2末端激酶,以及内质网应激反应的激活。这些细胞蛋白水平的改变导致对增殖,迁移的抑制,和癌细胞凋亡的促进。[2] Bortezomib能够渗透到细胞,并抑制蛋白酶体介导的细胞内长寿蛋白水解,抑制50%蛋白质水解的浓度为∼0.1 μM。Bortezomib对衍生自美国国家癌症研究所(NCI)多重人类肿瘤的一组60个癌细胞系的IC50值为7 nM。PC-3细胞用Bortezomib (100 nM)处理8小时导致细胞积聚在G2-M期,相应的G1期细胞数量减少。Bortezomib在24和48小时杀死PC-3细胞,IC50分别为100和20 nM。Bortezomib治疗16-24小时后诱导细胞核缩合。Bortezomib在低至100 nM浓度下以时间依赖的方式导致PARP裂解,在处理24小时后产生效果。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NVPZeopRS3m2b4TvfIlkKEG|c3H5 NHT6V3c2OCEQvF2= NX\3[|Q2PDhiaB?= M4TFOGROW09? MYDLbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUml MWKxNFQ6QTZ2Mx?=
OVCA 429 NX3YdIlQTnWwY4Tpc44hSXO|YYm= MUGzNFAhdk1? MVi0PEBp M4X0VGROW09? NFThOmhFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> MV[xNFk6QTd4Nh?=
RPMI8226 Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXRZ5NLOTByIH7N NWfsPXlpPDhiaB?= MXPEUXNQ NGHafWtKSzVyPUOwJI5O M2HlfFEyOzB4NEi5
Dox40 M3fH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTWNVAxKG6P NELleno1QCCq M{LGNWROW09? NG[3eFVKSzVyPUSwJI5O MXGxNVMxPjR6OR?=
MR20 M{jQcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxNFAhdk1? M1\MO|Q5KGh? NUX5ephxTE2VTx?= NXzteWVLUUN3ME2yNEBvVQ>? MkfVNVE{ODZ2OEm=
LR5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXFeXoyODBibl2= NGXEPGQ1QCCq NUDofIRbTE2VTx?= NYT4coNkUUN3ME2yNEBvVQ>? NXrMWGVyOTF|ME[0PFk>
U266 NF63[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVyxNFAhdk1? NXfwUGFMPDhiaB?= MWjEUXNQ M3HCfmlEPTB;MzDuUS=> NVjpPIFjOTF|ME[0PFk>
IM-9 NVTn[YlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\WS4YyODBibl2= MoDuOFghcA>? MVTEUXNQ NGDCdoVKSzVyPU[gcm0> NIjUNWIyOTNyNkS4PS=>
Hs Sultan NEDDXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF73ZnEyODBibl2= MUO0PEBp M4\vVmROW09? NH72OG5KSzVyPUKwJI5O NYe0NWVyOTF|ME[0PFk>
PAM-LY2 NXribXBoTnWwY4Tpc44hSXO|YYm= MYSxNFAhdk1? Ml:wNVIhcA>? NWDLSZNQTE2VTx?= M1LIbmlvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;u NUDKZ5V5OTF|NUC5NVM>
PAM 212 M1zNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jXR|ExOCCwTR?= NX7ncVNPPzJiaB?= NHu0eYhFVVOR MVTJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MkThNVE{PTB7MUO=
PAM-LY2 NH;Hc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nXXFExOCCwTR?= MUO3NkBp NFHifYZFVVOR MXXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NUXYW2pEOTF|NUC5NVM>
B4B8 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfMNVAxKG6P NXHMZ5RiPzJiaB?= M2rBVmROW09? Mn3HTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NV7PXJdDOTF|NUC5NVM>
B7E3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf4OmQyODBibl2= NGfXUnM4OiCq NE[w[HVFVVOR MXzJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MWixNVM2ODlzMx?=
UM-SCC-9 M3zaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PsV|ExOCCwTR?= MYO3NkBp NH:5eYZFVVOR MmW2TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NHzQNZEyOTN3MEmxNy=>
UM-SCC-11B NXu2NlFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i2NVExOCCwTR?= NH;5RmI4OiCq NXe4SHFYTE2VTx?= MYLJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NY\hU3RKOTF|NUC5NVM>
H460 M3y3cWZ2dmO2aX;uJGF{e2G7 MofNNVAh|ryP NWjMXVd{OjRiaB?= NVL6dYFXTE2VTx?= NIDuNoJKdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2 NXradmtXOTJ2OUKxNVc>
U266 NYrGXWhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn61OVAxKG6pL33s M2\qcVQ5KGh? MoTUSG1UVw>? Ml\LTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NWLiO5Y1OTJ4M{G2NVk>
ARH77 M{Ph[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HtNFUxOCCwZz;tcC=> NEDhVmI1QCCq MVnEUXNQ MkfwTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MYGxNlY{OTZzOR?=
WAD-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvsRogzPTByIH7nM41t M3f4T|Q5KGh? NHPqWllFVVOR Mn2xTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NXjlfmhJOTJ4M{G2NVk>
U266/LR7 M2WwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm1NFAhdmdxbXy= M12weFQ5KGh? Mlr4SG1UVw>? NGXqOmFKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NFHldo0yOjZ|MU[xPS=>
U266/dox4 M{O0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\KXVUxOCCwZz;tcC=> M4\Pc|Q5KGh? MVjEUXNQ M17QWmlvcGmkaYTzJINmdGxiZ4Lve5Rp NIfRV4QyOjZ|MU[xPS=>
RPMI8226/LR5 NXX4WYhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzZOVAxKG6pL33s MlvIOFghcA>? NGrIUGdFVVOR NVjFcop3UW6qaXLpeJMh[2WubDDndo94fGh? MlLTNVI3OzF4MUm=
H460 NULCTYdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHKzUHAyOCEQvF2= MlHnO|IhcA>? NU\IfHA{TE2VTx?= M{HUTGlEPTB;MUCwJI5O NVXKSGtzOTJ4M{G2NlA>
H358 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLmNVAh|ryP NFWx[WY4OiCq M1TwVWROW09? NFy1TVRKSzVyPUewJI5O MlLzNVI3OzF4MkC=
H322 MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOxNEDPxE1? MXO3NkBp NVq4OG55TE2VTx?= NGnzPGdKSzVyPU[yNEBvVQ>? NVXFd2R7OTJ4M{G2NlA>
H460 MojZSpVv[3Srb36gRZN{[Xl? NY\BdlJ4OTByIH7N M1j2OlI1KGh? NUXtfYlFTE2VTx?= MWXJcoR2[2W|IFeyMW0ueGijc3WgZZJz\XO2IHHu[EB1fWK3bHnuJIF{e2WvYnz5MYRqe2G|c3XtZox6 M3eyclEzPjNzNkKw
LNCap-Pro5 M{jpVmZ2dmO2aX;uJGF{e2G7 NHnCSXAyKM7:TR?= NX7OOJhlPCCq Mmq2SG1UVw>? M{L1OHN1[WKrbHn6[ZMheDV| NFi4O2oyPDZzMkWzNi=>
T29 MljiRZBweHSxc3nzJGF{e2G7 NELYNm42OCCwTR?= M3\WZ|Q5KGhi M3TCSmROW09? M4HPbmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MX2xOlc4QDF5OR?=
T29Kt1 MWHBdI9xfG:|aYOgRZN{[Xl? Mo\XOVAhdk1? NXvMV2JSPDhiaDC= MYLEUXNQ MWXJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NXzhVYc1OTZ5N{ixO|k>
HCT116 MnvCRZBweHSxc3nzJGF{e2G7 NHrmRng2OCCwTR?= NITzRWE1QCCqIB?= NUDOUHNMTE2VTx?= MVzJcoR2[2W|IHPlcIwh[XCxcITvd4l{ Ml72NVY4PzhzN{m=
HKe-3 M{DGeGFxd3C2b4Ppd{BCe3OjeR?= M{XNdFUxKG6P NX\idZd1PDhiaDC= Mn\hSG1UVw>? NYq0R5ZsUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NYDzRW1DOTZ5N{ixO|k>
NB-1691 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzpbYwyKM7:TR?= MXi3NkBp NWfqU|d7UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEWl MX2xO|Y5QTZ6NB?=
CHLA-255 M3WxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH3e|NHOSEQvF2= MV:3NkBp M3LXeGlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB{JR?= NU\SSIdZOTd4OEm2PFQ>
SK-N-AS M4Pwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLHNUDPxE1? M4PjT|czKGh? NYjwNGg1UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=> NWq1R|czOTd4OEm2PFQ>
NB-1691 NG\MWIhHfW6ldHnvckBCe3OjeR?= M2DBS|ExKG6P M2TOUVI1KGh? MVfTbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPl NULDfnhDOTd4OEm2PFQ>
CHLA-255 NWmyW3JqTnWwY4Tpc44hSXO|YYm= MnTwNVAhdk1? M{m0R|I1KGh? MnnLUY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V? MmTZNVc3QDl4OES=
RPMI 8226 M3rLbWZ2dmO2aX;uJGF{e2G7 Mon6NlAhdk1? NGTCbHY5KGh? MYTTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NIXlWogyQTR|NkC1NC=>
MM.1S MYrGeY5kfGmxbjDBd5NigQ>? Ml;YNlAhdk1? MVi4JIg> NGT5W2tUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MXuxPVQ{PjB3MB?=
U266 MX;GeY5kfGmxbjDBd5NigQ>? MnPjNlAhdk1? MVi4JIg> M3zoOHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NUfNTXF7OTl2M{[wOVA>
OPM1 NG[4V|dHfW6ldHnvckBCe3OjeR?= MWSyNEBvVQ>? NEXjXJo5KGh? MY\TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NUW5ZllEOTl2M{[wOVA>
INA6 M1LkWWZ2dmO2aX;uJGF{e2G7 NIL1XG8zOCCwTR?= Ml6wPEBp NYrHNZA4W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NVjzVHNmOTl2M{[wOVA>
OPM2 NY\k[W5TTnWwY4Tpc44hSXO|YYm= NHPqZpkzOCCwTR?= NITIWHg5KGh? NUS3RpA2W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MofZNVk1OzZyNUC=
RPMI 8226 M37LeWZ2dmO2aX;uJGF{e2G7 NWXIV|RKOjBibl2= MV64JIg> NWjnR2E5UW6mdXPld{BFVkFic4nueIhme2m| MnH2NVk1OzZyNUC=
BaF/3 NFHv[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Tk[VExOCCwTR?= NVLzXG46PDhiaB?= MY\JR|UxRTZwMjDuUS=> MXqyNFMxPTZ7Mh?=
BaF/3-p210 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjIeIsyODBibl2= MnmxOFghcA>? NWrhRo1OUUN3ME20Mlchdk1? M2q3UVIxOzB3Nkmy
TCC-S NIPGe|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojuNVAxKG6P MnWyOFghcA>? M3jGemlEPTB;Mj64JI5O MWWyNFMxPTZ7Mh?=
BaF/3 NIf1NW1HfW6ldHnvckBCe3OjeR?= M1HnW|Yhdk1? M3ntcVQ5KGh? MWXJcoR2[2W|IHGg[5Jm[XRiR{GgZ4VtdC2leXPs[UBienKnc4S= MVOyNFMxPTZ7Mh?=
BaF/3-p210 NGWxbpNHfW6ldHnvckBCe3OjeR?= Ml3nOkBvVQ>? MYO0PEBp M17VUmlv\HWlZYOgZUB{dGmpaISgS|Eh[2WubD3jfYNt\SCjcoLld5Q> MlzFNlA{ODV4OUK=
BaF/3-p210 MlrjSpVv[3Srb36gRZN{[Xl? MX22JI5O NGjMU20zPCCq MUfS[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gZY5lKHSqZTDhZ5Rqfmm2eTDv[kBT[g>? MUmyNFMxPTZ7Mh?=
Raji M1fwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLWNUDPxE1? NVLzUZNEOjRiaB?= M{H3fHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MV2yNVE4ODl6OB?=
LCL-1 Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnsU|BsOSEQvF2= MWSyOEBp NFHSO4hT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MnvxNlEyPzB7OEi=
LCL-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\Kc2k{OSEQvF2= NXPhZ2xiOjRiaB?= Mlm4VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M2rmOFIyOTdyOUi4
BJAB MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPMdncyKM7:TR?= MVeyOEBp NUHEUIdIWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MYGyNVE4ODl6OB?=
SNT-13 NVPP[Wt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj6NUDPxE1? MYmyOEBp NH;MN2tT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NVP1cndtOjFzN{C5PFg>
SNT-16 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID1eWQyKM7:TR?= MnTFNlQhcA>? NXfqcppuWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M2\heFIyOTdyOUi4
Jurkat NVu1O2FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrmRYFwOSEQvF2= NU\SU45yOjRiaB?= M{DYSXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MXeyNVE4ODl6OB?=
KAI-3 M3i5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfJZY4yKM7:TR?= MYWyOEBp NGfqbXlT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MnvKNlEyPzB7OEi=
SNK-6 NXTReJVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ToflEh|ryP NVnYUFZ6OjRiaB?= NIHDWIJT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= Ml\tNlEyPzB7OEi=
KHYG-1 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnftNUDPxE1? M4e4W|I1KGh? Ml65VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MWSyNVE4ODl6OB?=
SNT-16 NVO4VVRbSXCxcITvd4l{KEG|c3H5 NYTQUHRIOSEQvF2= M2\PV|YhcA>? Mn\tTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUOyNVE4ODl6OB?=
Jurkat NXvEbIlCSXCxcITvd4l{KEG|c3H5 MV2xJO69VQ>? Ml[3OkBp NFvUOY9KdmS3Y3XzJINmdGxiYYDvdJRwe2m| NVTTNY1UOjFzN{C5PFg>
KAI-3 NE\aNGZCeG:ydH;zbZMhSXO|YYm= MYixJO69VQ>? M1HNTFYhcA>? MkDKTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1;UW|IyOTdyOUi4
KHYG-1 NHKydmxCeG:ydH;zbZMhSXO|YYm= NX75fWNDOSEQvF2= MoPGOkBp M2jqR2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MkPLNlEyPzB7OEi=
SNT-13 M4XXUmFvfGm4aYLhcEBCe3OjeR?= MV6xJO69VQ>? NEnVXWIzPCCq M3nxUWlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? M3O1fVIyOTdyOUi4
SNT-16 M4XGXmFvfGm4aYLhcEBCe3OjeR?= MUCxJO69VQ>? MnO3NlQhcA>? MVXJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NVTpWmNOOjFzN{C5PFg>
KAI-3 NH3EU2NCdnSrdnnyZYwhSXO|YYm= NXvtTZp[OSEQvF2= NFPSTXIzPCCq MoHYTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NXjKRok6OjFzN{C5PFg>
SNK-6 Mof2RY51cX[rcnHsJGF{e2G7 MWmxJO69VQ>? NInvOIozPCCq M3TuRmlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? NHO4VWEzOTF5MEm4PC=>
RAW 264.7 NInX[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6xNFAhdk1? M2m1NlQ5KGh? M2XIV3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MWiyNlQzPzF3NB?=
A375 M1X0NWFxd3C2b4Ppd{BCe3OjeR?= MWexNEBvVQ>? MV:yOEBp M1LmTWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2fTcFI{ODd7MEiz
BLM NEjNWGpCeG:ydH;zbZMhSXO|YYm= NYe2eFVCOTBibl2= MnvFNlQhcA>? M2jhSmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M13QZlI{ODd7MEiz
A375 NEW3Z2tCfXSxcHjh[5khSXO|YYm= NFrRXlEyOCCwTR?= NH7PWXkyOiCq NGPPVZFKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> M4n5PVI{ODd7MEiz
BLM MYDBeZRweGijZ4mgRZN{[Xl? NHnNNJcyOCCwTR?= MkjENVIhcA>? NX7afIFLUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> NHHYV3IzOzB5OUC4Ny=>
H1299 M1XYVWFxd3C2b4Ppd{BCe3OjeR?= NHrEWFc5OCCwTR?= NUfmWHFEOjRiaB?= M4PlS2ROW09? M{PEU3NmdnOrdHn6[ZMhVlOFTFOgZ4VtdHNidH:gUXNENWSncnn2[YQhcUN7LXnu[JVk\WRiYYDvdJRwe2m| M4O5[FI2OzJ|Nkmz
Hut-78 MnmySpVv[3Srb36gRZN{[Xl? MVOxNFAhdk1? NHfLXHczPCCq NXy4c4FVTE2VTx?= MV;Ec5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVExKGW6cILld5Nqd25? MVGyOVY5OTN|NR?=
H9 MW\GeY5kfGmxbjDBd5NigQ>? MVexNFAhdk1? M{TlZlI1KGh? MYrEUXNQ NXO0Sm9CTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;u M3nFZlI2PjhzM{O1
HH NFXrcHhHfW6ldHnvckBCe3OjeR?= NH75c4syODBibl2= NEnkcJMzPCCq MVvEUXNQ M2\ibIRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?= NY\HWFBQOjV4OEGzN|U>
Hut-78 MVHNbYdz[XSrb36gRZN{[Xl? NV;ZUVlTOTByIH7N NXLDdnF4OjRiaB?= MkTaSG1UVw>? MmXkVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlyJR?= NFrBXHMzPTZ6MUOzOS=>
HH NY\EXINRVWmpcnH0bY9vKEG|c3H5 NGrKcIMyODBibl2= NFfGT4wzPCCq NEH4NVVFVVOR M2DhWXJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW= MX[yOVY5OTN|NR?=
U937 NV6zbHZUTnWwY4Tpc44hSXO|YYm= NYXE[lc3OTByIH7N MUm2JIg> NHu5ZpNKdmS3Y3XzJGlNNThiZYjwdoV{e2mxbjDpckBNWFNvc4TpcZVt[XSnZDDVPVM4KG2jY4LvdIhi\2W| MmC1NlU4QTF2N{e=
human PBMC MoroSpVv[3Srb36gRZN{[Xl? M{P4OVExOCCwTR?= M3;se|I1KGh? NWXuZWJNUW6mdXPld{BKVC16IILlcIVie2V? MYiyOVc6OTR5Nx?=
ES6 NX24UGRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\6TWM2OD1yLkCwNlEhdk1? NIfScldUSU6JRWK=
SK-UT-1 NXTSNXB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf2TWM2OD1yLkG2N{BvVQ>? M3LjWXNCVkeHUh?=
SH-4 M3rWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMUezJI5O NVnFcHdCW0GQR1XS
TE-9 M4XwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7tSId[UUN3ME2wMlE5OiCwTR?= MXTTRW5ITVJ?
A253 NV;4d3ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzSTWFKSzVyPUCuNlA5KG6P NUXGO4FTW0GQR1XS
no-10 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ftcWlEPTB;MD6yNUBvVQ>? NUX5c4FCW0GQR1XS
MMAC-SF MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELmTIpKSzVyPUCuNlE3KG6P NITscphUSU6JRWK=
A101D NXL4dGJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTPVIRvUUN3ME2wMlIzPSCwTR?= M3nCZnNCVkeHUh?=
NTERA-S-cl-D1 M2XjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMkSzJI5O NVL2OG5vW0GQR1XS
8-MG-BA M3Ti[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\Ocph{UUN3ME2wMlI2KG6P MV3TRW5ITVJ?
KNS-42 MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzSWoZKSzVyPUCuNlU5KG6P NIH2S|BUSU6JRWK=
LXF-289 M2SzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjjVXYyUUN3ME2wMlI3QSCwTR?= NIfZd3hUSU6JRWK=
OVCAR-4 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7xVpdKSzVyPUCuNlg6KG6P NEfDVHVUSU6JRWK=
LOUCY NWHVWIs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXiwW4xZUUN3ME2wMlI6OyCwTR?= NHfwe5FUSU6JRWK=
BB65-RCC NY\NNmVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG2TWM2OD1yLkOwOEBvVQ>? NGDUUVlUSU6JRWK=
D-542MG M4XFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor1TWM2OD1yLkOyPUBvVQ>? MkX0V2FPT0WU
ONS-76 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\jTWM2OD1yLkOzJI5O MlTnV2FPT0WU
BB30-HNC MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LnZmlEPTB;MD6zN|Uhdk1? NVjsNpB[W0GQR1XS
KS-1 M1rJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXsTWM2OD1yLkO0JI5O Mn70V2FPT0WU
A388 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M322cWlEPTB;MD6zOVYhdk1? MVzTRW5ITVJ?
ES8 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzr[lM4UUN3ME2wMlQhdk1? MmHjV2FPT0WU
MZ2-MEL M3\q[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrscmtKSzVyPUCuOFA4KG6P MWHTRW5ITVJ?
HCC2998 MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fkfWlEPTB;MD60NVIhdk1? MX7TRW5ITVJ?
D-247MG NY\jVnA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITFfWpKSzVyPUCuOFE{KG6P NXXvcFdWW0GQR1XS
ACN NWiyNYhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLjTWM2OD1yLkSxO{BvVQ>? NF;rRVlUSU6JRWK=
LB2518-MEL NVPCSoJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLiTWM2OD1yLkSyOUBvVQ>? NEjIN4tUSU6JRWK=
ES1 NUK1d3FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnEe41KSzVyPUCuOFMhdk1? MlnwV2FPT0WU
HCE-T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDhTWM2OD1yLkSzPUBvVQ>? MoLzV2FPT0WU
OS-RC-2 NEfHeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwNESgcm0> MmH1V2FPT0WU
MFH-ino MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4SxVGlEPTB;MD60OFMhdk1? M4K3NXNCVkeHUh?=
OCUB-M NF3sV|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnzPFhKSzVyPUCuOFQ4KG6P MX;TRW5ITVJ?
CP66-MEL NFXUZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHjO3lWUUN3ME2wMlQ4OyCwTR?= NVHoO494W0GQR1XS
LB771-HNC NF;GZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjqcZpKSzVyPUCuOFc1KG6P Mk\tV2FPT0WU
DSH1 NV[3c2htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwNEigcm0> MVHTRW5ITVJ?
HUTU-80 MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L5ZmlEPTB;MD61N|Mhdk1? NIPCdpVUSU6JRWK=
CESS NUPufHBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HWTGlEPTB;MD61N|ghdk1? NYPQUo5rW0GQR1XS
NCI-H747 NEjYcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXwVYlPUUN3ME2wMlU{QSCwTR?= NFm3UYZUSU6JRWK=
HT-144 M3ewVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HFRmlEPTB;MD61O|Yhdk1? NHrO[ldUSU6JRWK=
COLO-829 NIrTdJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjsTWM2OD1yLk[xOEBvVQ>? M2izNHNCVkeHUh?=
A4-Fuk NGrWcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwNkKzJI5O M4ToSXNCVkeHUh?=
GI-ME-N M4HMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L4fmlEPTB;MD62N|Qhdk1? Mn[5V2FPT0WU
LB831-BLC M{jMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwNkSxJI5O MW\TRW5ITVJ?
HOP-62 NEPlVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPQblVKSzVyPUCuOlQ4KG6P MX\TRW5ITVJ?
BB49-HNC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHDWIJKSzVyPUCuOlUzKG6P MkfWV2FPT0WU
D-336MG M1f5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7OTWM2OD1yLk[1O{BvVQ>? NVLn[2NoW0GQR1XS
TK10 NWnVXGdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M176XWlEPTB;MD62O|khdk1? MUHTRW5ITVJ?
Ramos-2G6-4C10 M33Pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT0TWM2OD1yLk[5N{BvVQ>? MmewV2FPT0WU
LB373-MEL-D NGjUVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnuWmtKSzVyPUCuO{BvVQ>? NXr1T4pbW0GQR1XS
SF126 NYjKNWhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXEb|VKSzVyPUCuO|AyKG6P MWLTRW5ITVJ?
UACC-257 M2HZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwN{Ggcm0> MlX1V2FPT0WU
KINGS-1 NXrvPItKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3aTWM2OD1yLkeyNkBvVQ>? NI\2blVUSU6JRWK=
LS-513 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7XTWM2OD1yLkezPUBvVQ>? MlvXV2FPT0WU
GI-1 M4DoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLDcZJKSzVyPUCuO|Y1KG6P NYXQfWR1W0GQR1XS
ES7 M4HiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPnU3JKSzVyPUCuO|Y3KG6P MVLTRW5ITVJ?
LB2241-RCC NIjmd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH0TYxIUUN3ME2wMlgxPCCwTR?= M{n6U3NCVkeHUh?=
D-263MG NInZboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwOEC3JI5O NUnYVnljW0GQR1XS
SW684 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rpVGlEPTB;MD64NlEhdk1? M33jVHNCVkeHUh?=
ML-2 M2D0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz0TWM2OD1yLkiyNUBvVQ>? MkWwV2FPT0WU
SK-LMS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTSPG5KSzVyPUCuPFU1KG6P MVjTRW5ITVJ?
TE-5 NWHpcnVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e1dGlEPTB;MD64OlUhdk1? Mk\FV2FPT0WU
QIMR-WIL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwOEi5JI5O NIDaVG5USU6JRWK=
NCI-H1355 M4fR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwOEm1JI5O M{nufXNCVkeHUh?=
SNB75 M4fqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\t[ndpUUN3ME2wMlkyOiCwTR?= Mmr5V2FPT0WU
RXF393 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXOTWM2OD1yLkmxOEBvVQ>? M{XJWHNCVkeHUh?=
IST-MEL1 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDKR2s6UUN3ME2wMlkyPyCwTR?= M4PWN3NCVkeHUh?=
SF268 MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwOUKzJI5O M1vjSnNCVkeHUh?=
KALS-1 Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX1bnFKSzVyPUCuPVI2KG6P M4KwXHNCVkeHUh?=
HC-1 NFLSd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\oXJZKSzVyPUCuPVc2KG6P NETwc29USU6JRWK=
SW872 NWDGWJplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrEfFBKSzVyPUCuPVk3KG6P MY\TRW5ITVJ?
PSN1 MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW2UGNQUUN3ME2xMlAyKG6P MlfoV2FPT0WU
TE-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnxTWM2OD1zLkCzJI5O M4PVTnNCVkeHUh?=
TE-10 NHTsSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[wdJNKSzVyPUGuNFMhdk1? NVnLVIlRW0GQR1XS
RKO MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPURplKSzVyPUGuNFYhdk1? Mmq2V2FPT0WU
LC-2-ad MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHQTWM2OD1zLkC4JI5O M4PhZnNCVkeHUh?=
SK-MM-2 Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHQZ29KSzVyPUGuNFkhdk1? MkK2V2FPT0WU
VA-ES-BJ NInUc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPTOXFKSzVyPUGuNFkhdk1? MUHTRW5ITVJ?
MZ7-mel NXPvbHl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7oemJYUUN3ME2xMlA6KG6P M17HcnNCVkeHUh?=
D-392MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPyTWM2OD1zLkGgcm0> NFrmW2FUSU6JRWK=
CCRF-CEM Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrGOWJKSzVyPUGuNVMhdk1? NWrnZ3FvW0GQR1XS
EM-2 NVLrSVg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwMU[gcm0> MoW5V2FPT0WU
HAL-01 M1Txbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;oWWlEPTB;MT6xPEBvVQ>? NFrXfGFUSU6JRWK=
TE-8 NVq0RWxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwMUmgcm0> NVW4S2ZbW0GQR1XS
NCI-H1882 NVfnNGxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L6[2lEPTB;MT6yJI5O NY\IXWlXW0GQR1XS
Daudi NI\jVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTh[pRmUUN3ME2xMlIzKG6P NXzHW2V5W0GQR1XS
BL-41 M1nBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwMkWgcm0> NYe0epJJW0GQR1XS
SR MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO0[FU3UUN3ME2xMlI2KG6P NGL2SZNUSU6JRWK=
KM12 MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwMkegcm0> NIHG[XFUSU6JRWK=
K5 NFn2VnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWyTWM2OD1zLkK4JI5O MWTTRW5ITVJ?
A3-KAW NYjzWWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnrdWNTUUN3ME2xMlI5KG6P Mn7hV2FPT0WU
CMK NYniSGw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnofW51UUN3ME2xMlI6KG6P NWLPXGxJW0GQR1XS
Calu-6 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\SZWhKSzVyPUGuNlkhdk1? MVXTRW5ITVJ?
IST-SL2 NFPrd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXsTY9KSzVyPUGuN|Ehdk1? MkflV2FPT0WU
OPM-2 MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwM{Ogcm0> MnvGV2FPT0WU
DU-4475 M4PQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny5TWM2OD1zLkO2JI5O NUm4[WVKW0GQR1XS
ECC12 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\Ydo1KSzVyPUGuN|chdk1? M1f5XXNCVkeHUh?=
L-540 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHu[HpKSzVyPUGuN|chdk1? NFTnenVUSU6JRWK=
CAS-1 NYSwOXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrvfIg5UUN3ME2xMlM4KG6P M4n2SHNCVkeHUh?=
PF-382 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\2XWNKSzVyPUGuOFchdk1? NWPnRXdVW0GQR1XS
LS-411N MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwNUOgcm0> M1m5WnNCVkeHUh?=
NCI-H69 M3Pr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3odFlKSzVyPUGuOVQhdk1? NHO2bopUSU6JRWK=
NB12 NYPSUos2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHSTWM2OD1zLkW2JI5O MlO1V2FPT0WU
HEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf1ZnhKSzVyPUGuOlEhdk1? M2fwT3NCVkeHUh?=
GCIY NXL4eWFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LrVmlEPTB;MT62NkBvVQ>? NYXR[m14W0GQR1XS
EHEB NH73dJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwNkegcm0> NIniRnVUSU6JRWK=
TGBC1TKB M1Wy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljZTWM2OD1zLkexJI5O M3n0dnNCVkeHUh?=
KURAMOCHI M4rTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLoNHJGUUN3ME2xMlczKG6P NGXHUm5USU6JRWK=
U-266 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rITGlEPTB;MT63OkBvVQ>? MkHVV2FPT0WU
LC4-1 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHETWM2OD1zLke5JI5O M375W3NCVkeHUh?=
NCI-H2126 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HrO2lEPTB;MT64JI5O MofDV2FPT0WU
NCI-H1092 NX3CeHlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjWV45OUUN3ME2xMlghdk1? Mlu3V2FPT0WU
GB-1 NYq4dIlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P6e2lEPTB;MT64NUBvVQ>? MXHTRW5ITVJ?
MV-4-11 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHYXWdyUUN3ME2xMlgzKG6P MkjVV2FPT0WU
Becker NV:2THhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PVTWlEPTB;MT64N{BvVQ>? NVzZS4NEW0GQR1XS
MPP-89 MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwOEmgcm0> Mly5V2FPT0WU
BE-13 NF3sO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwOUOgcm0> MV\TRW5ITVJ?
697 NXH6T|gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnxdFdKSzVyPUGuPVkhdk1? M4LmVnNCVkeHUh?=
NKM-1 NFW5WpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHzenp2UUN3ME2yJI5O MXvTRW5ITVJ?
NB13 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L2XmlEPTB;MjDuUS=> NXXMUlNNW0GQR1XS
LS-123 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTscWJKSzVyPUKuNFIhdk1? M4TOd3NCVkeHUh?=
NB17 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn35TWM2OD1{LkC0JI5O M3nVPHNCVkeHUh?=
LAN-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\ESWlEPTB;Mj6wOUBvVQ>? NVfzNVY3W0GQR1XS
EW-24 NVrmb2h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJwMEigcm0> NEHzZWFUSU6JRWK=
NOS-1 NH63[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi4UXZwUUN3ME2yMlEyKG6P MkjrV2FPT0WU
BL-70 NH;pUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrBTWM2OD1{LkGyJI5O NWTMcFJwW0GQR1XS
GT3TKB MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJwMUKgcm0> MYHTRW5ITVJ?
HH NIPx[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C1bmlEPTB;Mj6xN{BvVQ>? M3;od3NCVkeHUh?=
KE-37 NEPOb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;hcGlEPTB;Mj6xN{BvVQ>? NG[0[YJUSU6JRWK=
MOLT-4 NXT6T3ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;nTWM2OD1{LkGzJI5O MVXTRW5ITVJ?
EKVX M2PWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwMUSgcm0> NVPnc2lnW0GQR1XS
KGN MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jrN2lEPTB;Mj6xOUBvVQ>? MUPTRW5ITVJ?
ES4 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrkZWVKSzVyPUKuNVYhdk1? NHfPcFdUSU6JRWK=
SJSA-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jEcmlEPTB;Mj6yNUBvVQ>? NFTMcIRUSU6JRWK=
KMOE-2 NHfxRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXucINKSzVyPUKuNlMhdk1? NV\1RnpuW0GQR1XS
NB5 M3iwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXxTWM2OD1{LkK3JI5O M{C0TXNCVkeHUh?=
BC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCzSXNKSzVyPUKuN|Ehdk1? M1T4U3NCVkeHUh?=
NB10 NVHtPYM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC2TWM2OD1{LkOyJI5O NF;kb3VUSU6JRWK=
RPMI-8226 M2DWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn1[lM6UUN3ME2yMlM2KG6P M{fnRXNCVkeHUh?=
SCC-3 NIi4XW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTMO2R{UUN3ME2yMlM4KG6P NGjWdYFUSU6JRWK=
ARH-77 NGDSR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHudZRKSzVyPUKuN|ghdk1? MXnTRW5ITVJ?
NCI-H748 M3PhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP2XZkxUUN3ME2yMlM6KG6P NXvCUndYW0GQR1XS
KU812 NWnGUlljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjlTWM2OD1{LkSyJI5O M{nyOHNCVkeHUh?=
NCI-H64 NIXHN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfyTWM2OD1{LkS0JI5O M2Sz[HNCVkeHUh?=
NB69 MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDlTWM2OD1{LkS2JI5O MkPXV2FPT0WU
KNS-81-FD NEDjfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXITWM2OD1{LkS4JI5O NI\TbZFUSU6JRWK=
LB1047-RCC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJwNUegcm0> MmXuV2FPT0WU
EB-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzlfphKSzVyPUKuOlYhdk1? NUDSRpllW0GQR1XS
Mo-T NYfxeWtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrhcW1KSzVyPUKuO|Qhdk1? NVOxUpNyW0GQR1XS
EW-16 NHHnS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rvVmlEPTB;Mj63OUBvVQ>? NU\DbVFpW0GQR1XS
CTV-1 NVf3W4JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn6TWM2OD1{Lkigcm0> MmHBV2FPT0WU
ETK-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorNTWM2OD1{Lki0JI5O NV;hNGZwW0GQR1XS
C2BBe1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoiwTWM2OD1{Lki5JI5O NHzBdXJUSU6JRWK=
MOLT-16 M4Xn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwOEmgcm0> MUDTRW5ITVJ?
SW954 NX32V2lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJwOTDuUS=> MWDTRW5ITVJ?
HT MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi3TnJEUUN3ME2zMlAzKG6P NXX6cI5RW0GQR1XS
KARPAS-299 M3nSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTNwME[gcm0> M1LaVHNCVkeHUh?=
MONO-MAC-6 M1nKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNwMTDuUS=> MX3TRW5ITVJ?
CGTH-W-1 NHnSZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNwMTDuUS=> MnHGV2FPT0WU
SK-PN-DW NHvSdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW1TWM2OD1|LkG0JI5O M4PU[XNCVkeHUh?=
CW-2 NHXzTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3oS|VoUUN3ME2zMlIyKG6P M{K0fnNCVkeHUh?=
SK-N-DZ M4O0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nNeGlEPTB;Mz6yOkBvVQ>? NYnIW3VKW0GQR1XS
NEC8 NGfkXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTNwM{Wgcm0> MmT0V2FPT0WU
LB996-RCC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXHXG5CUUN3ME2zMlQhdk1? NVXuWGVGW0GQR1XS
DB MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHHTWM2OD1|LkSxJI5O MYTTRW5ITVJ?
TE-15 NYG4R494T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj5TWM2OD1|LkSzJI5O MY\TRW5ITVJ?
COR-L88 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzBV4lPUUN3ME2zMlQ4KG6P NXu1RWxMW0GQR1XS
LAMA-84 NH\hOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojQTWM2OD1|LkS5JI5O M3jpcHNCVkeHUh?=
MEG-01 NHriXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvR[|dSUUN3ME2zMlQ6KG6P MVvTRW5ITVJ?
LOXIMVI M3mzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjSTWM2OD1|LkWgcm0> MoLRV2FPT0WU
RPMI-8402 NIXzUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG5coFKSzVyPUOuOUBvVQ>? M2LlS3NCVkeHUh?=
KARPAS-45 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTlZmlRUUN3ME2zMlU1KG6P MmPRV2FPT0WU
HCC1187 NYPBTFFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNwNUSgcm0> NGPo[mdUSU6JRWK=
MZ1-PC NVraVVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3qR29KSzVyPUOuOVQhdk1? NE\UZo9USU6JRWK=
no-11 NHnZfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XicGlEPTB;Mz61OUBvVQ>? NIL2W4JUSU6JRWK=
EVSA-T MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzSd4RKSzVyPUOuOkBvVQ>? MkTBV2FPT0WU
DJM-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH1S45UUUN3ME2zMlY{KG6P MWTTRW5ITVJ?
COLO-684 M{DPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNwNk[gcm0> M2C2cnNCVkeHUh?=
NMC-G1 NWLJRm5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHyXm1KSzVyPUOuOlghdk1? M2f0PXNCVkeHUh?=
LC-1F NFXKXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7uTXY{UUN3ME2zMlc1KG6P MVnTRW5ITVJ?
RL95-2 NWizUolnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr0Vo5KSzVyPUOuO|khdk1? MU\TRW5ITVJ?
COLO-320-HSR M4P6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNwOUKgcm0> MVHTRW5ITVJ?
RCC10RGB MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYOyVnNSUUN3ME2zMlk{KG6P NIfHfWZUSU6JRWK=
HD-MY-Z Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTNwOUOgcm0> NWrCXGJqW0GQR1XS
NCI-H2141 NUHiWo9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7tTWM2OD12LkC1JI5O NHnmcndUSU6JRWK=
K-562 M1\HSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfETWM2OD12LkGyJI5O NGHHT4dUSU6JRWK=
NCI-H1648 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTRwMUOgcm0> MlW2V2FPT0WU
OMC-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPSc|RDUUN3ME20MlE5KG6P NVXp[lE3W0GQR1XS
LB647-SCLC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTRwMkKgcm0> MlTRV2FPT0WU
TE-12 M2rXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\2W2lEPTB;ND6yOUBvVQ>? Mk\rV2FPT0WU
NOMO-1 M{jsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XaSmlEPTB;ND6zN{BvVQ>? NInxPYdUSU6JRWK=
Raji MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3sTWM2OD12LkS2JI5O NHPy[Y5USU6JRWK=
NALM-6 M{jRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTwOohKSzVyPUSuOFkhdk1? M{G0UXNCVkeHUh?=
HL-60 NIDjUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3kfVNKSzVyPUSuOlchdk1? M{OySXNCVkeHUh?=
IST-SL1 M3PkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTRwNkigcm0> M3j3OnNCVkeHUh?=
MHH-PREB-1 NEf5UGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;3TWM2OD12Lki2JI5O M2jhRXNCVkeHUh?=
MHH-NB-11 Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\JdpdKSzVyPUSuPVEhdk1? Mkf5V2FPT0WU
JiyoyeP-2003 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof6TWM2OD13IH7N MWHTRW5ITVJ?
SBC-1 M1viemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzrTWM2OD13LkCxJI5O M{DQcHNCVkeHUh?=
CHP-126 M4raPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v5N2lEPTB;NT6wOkBvVQ>? MnP5V2FPT0WU
LU-139 NUX3cG9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXhe5B6UUN3ME21MlE{KG6P MnnWV2FPT0WU
NCI-SNU-5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\jTWZLUUN3ME21MlE4KG6P NYC4XmF4W0GQR1XS
SW962 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnrcoRKSzVyPUWuNlEhdk1? NH32SXlUSU6JRWK=
EW-1 M2DDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvqPW1KSzVyPUWuN|Ehdk1? NW\ieW05W0GQR1XS
NCI-H1417 NV;hb245T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTVwNUGgcm0> MWDTRW5ITVJ?
LU-65 Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkixTWM2OD13Lki0JI5O MWjTRW5ITVJ?
D-502MG NGL3TlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTZwM{egcm0> MUfTRW5ITVJ?
BC-3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTZwNkGgcm0> NUPWUm1FW0GQR1XS
GDM-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nEW2lEPTB;Nj63O{BvVQ>? NW\LXHdGW0GQR1XS
NCI-H2196 MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L0T2lEPTB;Nj64JI5O M{ThXXNCVkeHUh?=
NB1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjjfXZ6UUN3ME22Mlg5KG6P NH60[nZUSU6JRWK=
NCI-H345 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrOSW9nUUN3ME23MlIhdk1? NXX5NFVFW0GQR1XS
SU-DHL-1 M{LUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXicFRyUUN3ME23MlI1KG6P MmnPV2FPT0WU
JVM-2 MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfFXGdKSzVyPUeuNlghdk1? M3fZXHNCVkeHUh?=
LU-134-A MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTdwM{mgcm0> Mo\CV2FPT0WU
NCI-H1694 Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XtbWlEPTB;Nz61PEBvVQ>? NHvae4JUSU6JRWK=
NCI-SNU-16 NYXVUXhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTdwNkWgcm0> NHS1eHVUSU6JRWK=
L-363 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnXZ2V2UUN3ME23Mlchdk1? M1rBU3NCVkeHUh?=
KG-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\MZmlEPTB;Nz65OEBvVQ>? NEX3RXpUSU6JRWK=
MN-60 NFm1XWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\PXGlEPTB;OD6xOEBvVQ>? NWDDcnVwW0GQR1XS
NB6 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnyW2pKSzVyPUiuOFghdk1? NHf5cXRUSU6JRWK=
MLMA NX3TeIlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37XUGlEPTB;OD64OUBvVQ>? M3HUWXNCVkeHUh?=
ATN-1 M2PRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRThwOEmgcm0> M{LzV3NCVkeHUh?=
SK-NEP-1 M13VUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTlwMEGgcm0> NVf4ZZZRW0GQR1XS
DMS-114 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jsWmlEPTB;OT62NkBvVQ>? MYnTRW5ITVJ?
CTB-1 NVzi[GhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nPTGlEPTB;OT62O{BvVQ>? M3nHcnNCVkeHUh?=
NCI-H2081 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPnSYZKSzVyPUGwMlA6KG6P MXHTRW5ITVJ?
ES5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXpdVRKSzVyPUGwMlM5KG6P M3rUSXNCVkeHUh?=
HCC1599 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PD[GlEPTB;MUGuPVEhdk1? NH7kN21USU6JRWK=
NCI-H23 NX[4bI1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXVTWM2OD1zMj6xNkBvVQ>? NXr4PHY{W0GQR1XS
NCI-H1581 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXlelFKSzVyPUGyMlI5KG6P M1LnZnNCVkeHUh?=
JVM-3 NGHwR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;rTmlEPTB;MUKuPVkhdk1? MknlV2FPT0WU
NCI-SNU-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP2TZJKSzVyPUGzMlE6KG6P MY\TRW5ITVJ?
NB7 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LKcWlEPTB;MUWuPVIhdk1? NYi4S3lVW0GQR1XS
JAR M1z6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D4dmlEPTB;MU[uNVMhdk1? M{PrbXNCVkeHUh?=
TGW MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\JTWM2OD1zNj60PEBvVQ>? MlW1V2FPT0WU
U-87-MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LRfmlEPTB;MU[uO|Yhdk1? MoHtV2FPT0WU
NCI-H1436 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLB[XFYUUN3ME2xO{4xOSCwTR?= NGToTopUSU6JRWK=
GOTO NIHRN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\z[oFKSzVyPUG3MlA3KG6P NYDFSJdRW0GQR1XS
COLO-800 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF5Lk[0JI5O M3\CV3NCVkeHUh?=
MFM-223 NWjES4VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O0VGlEPTB;MUeuPVEhdk1? M1;ZbHNCVkeHUh?=
EW-18 MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi2RXVPUUN3ME2xO{46PiCwTR?= NH\YeXpUSU6JRWK=
NB14 NIGze2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zIZ2lEPTB;MUeuPVghdk1? MlvTV2FPT0WU
EB2 M33JdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnixTWM2OD1zOD6wPEBvVQ>? MVrTRW5ITVJ?
EoL-1- NInXfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF6LkOxJI5O MofQV2FPT0WU
NCCIT Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF6LkO2JI5O MmKzV2FPT0WU
DG-75 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PrXWlEPTB;MUiuOlEhdk1? NFzwepZUSU6JRWK=
HCC2218 NULvRpRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXTTpFkUUN3ME2xPU42KG6P NUnze|RUW0GQR1XS
TE-6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LETWlEPTB;MkCuNFghdk1? MWnTRW5ITVJ?
SF539 NHHKdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\oV5dKSzVyPUKwMlY4KG6P NEXZdmtUSU6JRWK=
NCI-H446 NXTqN5Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XhO2lEPTB;MkGuNVghdk1? MV7TRW5ITVJ?
IST-MES1 M1vXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSySXZKSzVyPUKyMlc4KG6P MVXTRW5ITVJ?
NCI-H82 NX3McWh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\KXnFGUUN3ME2yN{4xOiCwTR?= MoTyV2FPT0WU
HCC2157 M1;GcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPETWM2OD1{Mz6xN{BvVQ>? MWHTRW5ITVJ?
EW-12 NYXMZ|N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJ|LkG3JI5O MV7TRW5ITVJ?
SIMA NH3mZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KxVmlEPTB;MkOuN|ghdk1? M2\OOnNCVkeHUh?=
DOHH-2 MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PUVmlEPTB;MkOuOFUhdk1? MofCV2FPT0WU
IM-9 M1rLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H0NGlEPTB;MkOuOVQhdk1? MYXTRW5ITVJ?
EC-GI-10 M{DDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ2LkKzJI5O NGTkfW9USU6JRWK=
HDLM-2 MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ2LkW0JI5O NFTYTmRUSU6JRWK=
LS-1034 NUfyWm1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJ3Lke1JI5O MVfTRW5ITVJ?
REH MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Pyc2lEPTB;Mk[uOFEhdk1? NWHHbmg5W0GQR1XS
LU-165 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDxTWM2OD1{Nj63NkBvVQ>? MnrXV2FPT0WU
NH-12 M1KxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPi[pVKSzVyPUK3MlY4KG6P NI\vcpVUSU6JRWK=
WSU-NHL NIHzbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLTXXJKSzVyPUK4MlM6KG6P MYTTRW5ITVJ?
ECC4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJ6Lke5JI5O MYLTRW5ITVJ?
OCI-AML2 M4DkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1SzbmlEPTB;MkmuOlkhdk1? MlvLV2FPT0WU
EW-3 NGfRbYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHexeG9KSzVyPUOwMlU6KG6P MVrTRW5ITVJ?
NCI-H526 MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C1RWlEPTB;M{KuOVQhdk1? NF7Od41USU6JRWK=
NCI-H719 NEe3fZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PTUmlEPTB;M{SuN|Ehdk1? M2TDV3NCVkeHUh?=
KARPAS-422 NEnFZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\JRoJRUUN3ME2zOU4xPCCwTR?= MX\TRW5ITVJ?
SK-MEL-1 NUTwfJpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjpdW5KSzVyPUO1MlE4KG6P MlfpV2FPT0WU
ES3 NEHMS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN3LkG5JI5O NIrx[JhUSU6JRWK=
UACC-812 MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;tTWM2OD1|NT60OEBvVQ>? NV3tSIx[W0GQR1XS
C8166 M3LE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uwdmlEPTB;M{WuO{BvVQ>? Ml\5V2FPT0WU
MDA-MB-134-VI MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTN3Lki3JI5O NYjTPWJiW0GQR1XS
D-283MED MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDKTWM2OD1|Nz63PUBvVQ>? NHTNV5lUSU6JRWK=
SHP-77 NGXMe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjnfWRXUUN3ME2zPE4xOyCwTR?= NWKzU4RtW0GQR1XS
NCI-H2227 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17uZWlEPTB;NECuOFkhdk1? NYnmbIRNW0GQR1XS
SKM-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPUblBmUUN3ME20Nk43OyCwTR?= NYCybY9JW0GQR1XS
L-428 M13uVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLvTWM2OD12Mz64OkBvVQ>? MmjrV2FPT0WU
RPMI-6666 M4S4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\oS4hHUUN3ME20OU45QSCwTR?= NWnsTlNTW0GQR1XS
NCI-H716 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\lTWM2OD12OD64NUBvVQ>? MkDvV2FPT0WU
DMS-79 M3XJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTVyLkexJI5O MlnoV2FPT0WU
RS4-11 NYnZdW1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\UU2RKSzVyPUWwMlg5KG6P M{DTSXNCVkeHUh?=
NCI-H720 M3;z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnFTWM2OD13MT6xNUBvVQ>? MkXwV2FPT0WU
MC-CAR MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO1VlRKSzVyPUWxMlUzKG6P M3m3N3NCVkeHUh?=
TALL-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTV|LkmxJI5O MWnTRW5ITVJ?
NCI-N87 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn5Om5KSzVyPUW0MlE5KG6P M3nZSnNCVkeHUh?=
P30-OHK MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHpdoVOUUN3ME21OE43OSCwTR?= NEP2SopUSU6JRWK=
LP-1 NIPzclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDZTWM2OD14MT6yPEBvVQ>? Mke3V2FPT0WU
YT Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjJSYdPUUN3ME22NU45KG6P NIPITmNUSU6JRWK=
MRK-nu-1 NV3rZmhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTI[mxKSzVyPU[xMlgzKG6P MUnTRW5ITVJ?
BT-474 NGHTZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDabHdKSzVyPU[1JI5O MX;TRW5ITVJ?
NCI-H322M NHLySJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnJSllKSzVyPU[2MlEyKG6P NXjrcmx2W0GQR1XS
NCI-H128 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rwZWlEPTB;N{SuO|chdk1? MUXTRW5ITVJ?
KMS-12-PE NInZeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\oR4dKSzVyPUe2MlI1KG6P M2fp[HNCVkeHUh?=
KP-N-YS MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTd4Lke0JI5O M4rmR3NCVkeHUh?=
ALL-PO NH2xZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13pTGlEPTB;N{euOlYhdk1? MU\TRW5ITVJ?
EW-13 NXz3emVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL4PXVKSzVyPUe3Mlc3KG6P MXnTRW5ITVJ?
EW-11 NWLzNJB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnJNpNlUUN3ME23PE42OiCwTR?= M2G5OXNCVkeHUh?=
SK-N-FI NX;BU|JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;qXopKSzVyPUiwMlIhdk1? M4SyW3NCVkeHUh?=
CAL-148 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRThzLki0JI5O M2LDTnNCVkeHUh?=
RL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULwW5lbUUN3ME24Ok4xQSCwTR?= NHfQV3VUSU6JRWK=
AM-38 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLCTWM2OD16OD6wPEBvVQ>? MkLnV2FPT0WU
RH-1 NFPRfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Ly[mlEPTB;OUmuPFUhdk1? M3nW[XNCVkeHUh?=
NCI-H1770 NX3IdpVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfrTWM2OD1zMEKuOFkhdk1? MXPTRW5ITVJ?
SIG-M5 NGjKenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT4bVRKSzVyPUGwOU4xPiCwTR?= M2P3O3NCVkeHUh?=
GR-ST MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[wZ2lEPTB;MUGzMlM1KG6P NFH5eWVUSU6JRWK=
ST486 M37rVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLkPZlIUUN3ME2xNVQvODZibl2= MYXTRW5ITVJ?
NCI-H1650 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fzTmlEPTB;MUG1MlI6KG6P NHPGNFRUSU6JRWK=
MHH-CALL-2 NVLDe|FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7SNYJpUUN3ME2xNVUvPyCwTR?= MV7TRW5ITVJ?
BV-173 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P4dmlEPTB;MUKyMlcyKG6P NV7xbVlzW0GQR1XS
MC116 NIPjVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DNNmlEPTB;MUS4Mlg2KG6P MVjTRW5ITVJ?
NCI-H524 M3y0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XmdWlEPTB;MUW5MlEhdk1? NGLhfY1USU6JRWK=
SCLC-21H MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWwdlExUUN3ME2xOVkvPDFibl2= M2r6S3NCVkeHUh?=
NCI-H1304 NXSxe3Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XVS2lEPTB;MU[5MlIyKG6P NFPvUmZUSU6JRWK=
NCI-H510A MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULtVlJ4UUN3ME2xPFUvOzdibl2= MUjTRW5ITVJ?
NCI-H209 NVHSeWdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHQU5U{UUN3ME2xPVYvPTJibl2= NVXCW4FzW0GQR1XS
KM-H2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjrUJhFUUN3ME2xPVcvODVibl2= M{PaWXNCVkeHUh?=
NCI-H1395 Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLKNG1KSzVyPUKxNE4yOyCwTR?= NGTT[YxUSU6JRWK=
NCI-H1155 M2fkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojFTWM2OD1{M{CuN|Ihdk1? MVXTRW5ITVJ?
COR-L279 Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\nWYtKSzVyPUK1Nk4yPyCwTR?= NFfKTGxUSU6JRWK=
NCI-H1299 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL1TWM2OD1{NkGuO|Ehdk1? NI\jWIVUSU6JRWK=
EW-22 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;4TWM2OD1{NkOuO|Uhdk1? MYHTRW5ITVJ?
SK-MEL-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL5TWM2OD1{OEGuPUBvVQ>? Mn3SV2FPT0WU
KASUMI-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ6Mz6wOUBvVQ>? NGjJSlNUSU6JRWK=
NCI-H187 M4WzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3SxdGlEPTB;Mki3MlA5KG6P M1\VbnNCVkeHUh?=
NCI-H2171 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PnXWlEPTB;Mki4MlkzKG6P NILq[2NUSU6JRWK=
LNCaP-Clone-FGC M3\kfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fjUmlEPTB;Mkm1MlI3KG6P NYLac5RVW0GQR1XS
NCI-H1522 NGOw[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\Oe2FKSzVyPUOwO{4xPSCwTR?= NHXVOpBUSU6JRWK=
SCH M1vKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXYV3ZXUUN3ME2zNlIvOjJibl2= MmraV2FPT0WU
THP-1 M1jLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPpSXlKSzVyPUOyNk43KG6P MnrBV2FPT0WU
SNU-C1 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTKTWM2OD1|NkKuNFkhdk1? M{HTdnNCVkeHUh?=
CA46 MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\6WpJKSzVyPUO3N{43OyCwTR?= MX7TRW5ITVJ?
NCI-H1963 NHzhXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfXZnRKSzVyPUO4Ok4yQSCwTR?= NGnwbZZUSU6JRWK=
DEL NWDXd3h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfQNFNKSzVyPUO5NU4zPyCwTR?= MojKV2FPT0WU
TUR NX;jUFhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTsTWM2OD1|OU[uOlEhdk1? M1P1WnNCVkeHUh?=
NCI-H226 NXrYOIR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDqOJlFUUN3ME20NFMvOjNibl2= NXXidGpLW0GQR1XS
COLO-668 NWewVINyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzMdZBkUUN3ME20NFMvPTdibl2= NGfySJhUSU6JRWK=
CPC-N NYnPXWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz0[IlKSzVyPUSwN{44PyCwTR?= MYDTRW5ITVJ?
NCI-H889 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\oPWFtUUN3ME20OlEvQTJibl2= MlzCV2FPT0WU
J-RT3-T3-5 NEPDSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrqfoNKSzVyPUWzNk42PyCwTR?= NH33XFJUSU6JRWK=
MSTO-211H NV3KW|lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2joVWlEPTB;NUe0MlI3KG6P NH;STWxUSU6JRWK=
SCC-15 M17YV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTZ4Nz60O{BvVQ>? NEPDb5dUSU6JRWK=
SUP-T1 NXnaO4VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm4WXNNUUN3ME22PFYvODRibl2= M2D2R3NCVkeHUh?=
DMS-153 NEL4XoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTd2Nj64N{BvVQ>? NYS0NGlnW0GQR1XS
MS-1 NH7RTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPaPHhWUUN3ME23OVkvPDJibl2= MXfTRW5ITVJ?
TC-YIK MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO0SmVKSzVyPUe4NU4xOSCwTR?= MUfTRW5ITVJ?
RPMI-8866 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHlXIt1UUN3ME2xNFA3NjJ6IN88US=> MWfTRW5ITVJ?
KY821 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn6TWM2OD1zMEO2MlA1KM7:TR?= M{np[nNCVkeHUh?=
P31-FUJ NXnDRlg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXuOlJKSzVyPUGxNVIvPzVizszN NVznUFJnW0GQR1XS
COLO-824 NHXze4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\CcFNmUUN3ME2xNlYyNjd6IN88US=> MWXTRW5ITVJ?
U-698-M Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfoWYVKSzVyPUKyOlIvOTVizszN Mm\TV2FPT0WU
TE-441-T NULBZ2Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJ3MkGuO{DPxE1? MoXVV2FPT0WU
IMR-5 NXTGOpQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTN2MEmuOlIh|ryP MVnTRW5ITVJ?
NCI-H1838 M{DQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfSco5{UUN3ME20NVg3NjN{IN88US=> NGLZWpdUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 Bortezomib单一用药的抗癌作用已在多发性骨髓瘤的异种移植模型,成人白血病,肺癌,乳腺癌,前列腺癌,胰腺癌,头颈癌,和结肠癌,以及在黑色素瘤中得到证实。[2]在Lewis肺癌模型中,口服bortezomib (1.0 mg/ kg,每天),服用18天引起肿瘤生长延迟,并减少转移数量。Bortezomib单一用药, 高达5 mg/kg剂量时显著降低乳腺癌细胞的存活率。在前列腺癌小鼠异种移植模型中,Bortezomib (1.0 mg/kg,每周一次)用药4周减少60%肿瘤生长。1.0 mg/kg Bortezomib给药4周导致胰腺癌小鼠异种移植物生长减少72%或84%,并导致肿瘤细胞凋亡增加。1.0 mg/kg Bortezomib显著抑制人浆细胞瘤异种移植物生长,增加肿瘤细胞凋亡和总存活率,并减少肿瘤血管生成。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[4]

+ 展开

动力学法:

在典型的动力学试验中,2.00 mL试验缓冲液(20 mM HEPES,0.5 mM EDTA,0.035% SDS,pH 7.8) 和 Suc-Leu-Leu-Val-Tyr-AMC溶于DMSO,加入3 mL荧光比色皿中,并将比色皿放置于荧光分光光度计的夹套细胞皿座。反应温度通过循环水浴维持在37℃。反应溶液达到热平衡后(5 分钟),1 μL−10 μL储存酶溶液加入培养皿。伴随AMC 从多肽AMC底物裂解的反应进程通过440 nm (λex= 380 nm)下荧光发射的增加监测。
细胞实验:

[5]

+ 展开
  • Cell lines: 人多发性骨髓瘤细胞系U266
  • Concentrations: ~10 μM
  • Incubation Time: 2天
  • Method:

    通过测定细胞吸收 MTT染料的情况而测定 Bortezomib对 MM和 BMSC 生长的抑制情况。每孔使用10 μL 5 mg/mL MTT对培养48小时的细胞进行脉冲处理,至少处理4小时, 随后加入100 μL 含0.04 N HCl的异丙醇 。使用分光光度计在 570 nm处测定吸光值。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 人浆细胞瘤异种移植物RPMI 8226
  • Formulation: 生理盐水
  • Dosages: 1mg/kg
  • Administration: i.v.,一周两次,使用4周,然后一周一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 384.24
化学式

C19H25BN4O4

CAS号 179324-69-7
稳定性 powder
in solvent
别名 LDP-341, MLM341

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03617484 Recruiting Mantle Cell Lymphoma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03829020 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Mayo Clinic|National Cancer Institute (NCI) March 1 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

相关Proteasome产品

Tags: 购买Bortezomib (PS-341) | Bortezomib (PS-341)供应商 | 采购Bortezomib (PS-341) | Bortezomib (PS-341)价格 | Bortezomib (PS-341)生产 | 订购Bortezomib (PS-341) | Bortezomib (PS-341)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID